Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
SGMT•FDA clearance and Phase 3 timing
Aug. 13 (Reuters) - Sagimet Biosciences Inc. (SGMT.O):
- Sagimet Biosciences receives FDA “study may proceed” letter and IND clearance for Phase 3 trial in acne in adolescent and adult patients.
- Sagimet Biosciences Inc.: Phase 3 clinical trial is on track to initiate in the second half of 2026.
- Sagimet Biosciences: Phase 3 trial on track to initiate in the second half of 2026.
